Dr. Rupenthal is an innovator in ocular drug delivery ideas. Her current research, co-funded by a Sir Charles Hercus Health Research Fellowship from the New Zealand Health Research Council, focuses predominantly on the development of stimuli-response ocular drug delivery systems with projects investigating implants responsive to ultrasound, light or a small electrical current. Since 2013,  it has been aim of the Buchanan Ocular Therapeutics Unit (BOTU) to translate ocular therapeutic related scientific research into the clinical setting, whether pharmaceutical, cell…